CML-Living with a Chronic Disease
A Live Telephone/Web Education Program Offering Live Spanish Interpretation Featuring International CML Expert Jorge Cortes, MD
Since the advent of targeted therapies, three of which are now approved for the treatment of newly diagnosed chronic phase CML, survival and quality of life for patients with CML has dramatically improved. Recent studies show that more than 90% of newly diagnosed, early stage CML patients can expect to survive long-term. Just as LLS was instrumental in funding the research which led to the development of imatinib (Gleevec(®)), LLS is also committed to ensuring that these treatment advances reach all patients. The telephone/web program on
To register for the
To register for CML-Living with a Chronic Disease in English, please visit www.LLS.org/programs.
For information on other LLS programs, please visit www.LLS.org or contact an Information Specialist at (800) 955-4572.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (® )(LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Founded in 1949 and( )headquartered in
SOURCE The Leukemia & Lymphoma Society